Clinical Trial Update: Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability trial of SCA-136 in healthy Japanese and non-Japanese female subjects has completed; sponsor Wyeth is now a part of Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SCA-136

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED